GlobeNewswire·Nov 9, 2026, 7:30 AM ET

Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors

Immuneering Corporation appointed Grant Bogle to its Board of Directors effective November 09, 2026.
Bogle brings over four decades of experience in oncology commercialization, sales, marketing, market access, corporate strategy, & board leadership.
Most recently served on the Nuvalent board prior to its 2026 acquisition by GlaxoSmithKline.
Previously acted as CEO of Epizyme, Inc., leading restructuring & facilitating its 2022 acquisition by Ipsen.
Formerly served as Chief Commercial Officer at TESARO, where he led the U.S. launch of ZEJULA for ovarian cancer & contributed to the company's 2019 acquisition by GlaxoSmithKline.
Held senior roles at Millennium Pharmaceuticals & McKesson Specialty Health, including leading early U.S. commercialization of VELCADE.
Bogle highlighted Immuneering's atebimetinib data showing a 17.3-month median overall survival in first-line pancreatic cancer & praised its potential for weight stability & tolerability.
Immuneering is conducting the global MAPKeeper 301 pivotal trial for atebimetinib in combination with chemotherapy for first-line pancreatic cancer.
The company's lead candidate is a Deep Cyclic Inhibitor of MEK designed to shrink tumors durably, preserve body mass, & minimize side effects.